Citi lifts GSK; Shore likes XPS Pensions

February 13, 2024 at 04:34 am EST

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

----------

FTSE 100

----------

Citigroup raises GSK to 'buy' (neutral) - price target 2,100 (1,700) pence

----------

DZ Bank cuts fair value for AstraZeneca to 10,400 (11,000) pence - 'hold'

----------

Goldman Sachs cuts Unilever price target to 4,505 (4,580) pence - 'neutral'

----------

Goldman Sachs raises M&G price target to 249 (240) pence - 'buy'

----------

RBC cuts Glencore price target to 520 (540) pence - 'outperform'

----------

FTSE 250

----------

JPMorgan cuts ITV price target to 105 (106) pence - 'overweight'

----------

Goldman Sachs cuts SSP price target to 255 (260) pence - 'neutral'

----------

RBC starts Breedon with 'outperform' - price target 575 pence

----------

Jefferies cuts Primary Health Properties price target to 114 (122) pence - 'buy'

----------

SMALL CAP

----------

Shore Capital Markets lifts XPS Pensions to 'buy' from 'hold'

----------

Berenberg cuts ITM Power price target to 70 (80) pence - 'hold'

----------

Comments and questions to newsroom@alliancenews.com

Market Closed - London S.E. Other stock markets 11:35:15 2024-04-26 am EDT			5-day change	1st Jan Change
1,653 ^GBX	+0.76%		+3.38%	+13.98%

Apr. 25	Sector Update: Health Care Stocks Drop in Afternoon Trading	MT
Apr. 25	GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	MT

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
FTSE MID 250 INDEX	19,824 PTS	+1.13%	+1.92%	-
ASTRAZENECA PLC	11,988 GBX	-0.32%	+9.52%	231B
FTSE 100	8,140 PTS	+0.75%	+3.09%	-
UNILEVER PLC	4,133 GBX	+1.25%	+8.45%	129B
GSK PLC	1,653 GBX	+0.76%	+3.38%	84.13B
S&P UNITED KINGDOM (PDS)	1,650 PTS	+0.76%	+3.55%	-
MSCI UNITED KINGDOM (STRD)	1,213 USD	+0.54%	+3.65%	-
GLENCORE PLC	469.5 GBX	+0.19%	-1.01%	71.07B
BREEDON GROUP PLC	364.5 GBX	+1.67%	-2.02%	1.56B
XPS PENSIONS GROUP PLC	255 GBX	+0.39%	+3.66%	654M
M&G PLC	199.4 GBX	+0.73%	-0.25%	5.81B
SSP GROUP PLC	196.7 GBX	-1.30%	+0.25%	1.95B
PRIMARY HEALTH PROPERTIES PLC	91.85 GBX	+0.93%	0.00%	1.53B
ITV PLC	70.5 GBX	+0.64%	+0.93%	3.5B
CITIGROUP INC.	62.66 USD	+1.41%	+5.95%	120B
ITM POWER PLC	51.1 GBX	+2.20%	-0.58%	393M

Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines	Apr. 25	MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement	Apr. 25	MT
Moody’s Affirms Haleon’s Ratings on Strong Operating Performance	Apr. 25	MT
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24	MT
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	Apr. 24
GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review	Apr. 24	MT
CureVac, GSK Launch Phase 1/2 Trial of Bird Flu Vaccine Candidate	Apr. 24	MT
GSK : Gets a Sell rating from JP Morgan	Apr. 24	ZD
GSK : Gets a Buy rating from Bernstein	Apr. 24	ZD
GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli	Apr. 24	CI
GSK: FDA priority review for endometrial cancer	Apr. 24	CF
GSK's Jemperli with chemotherapy accepted for priority review by FDA	Apr. 24	AN
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	Apr. 24	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	Apr. 24	RE
Edwards Lifesciences Corporation: The story continues	Apr. 23
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	Apr. 17	CI
GSK: shingles virus effective for over 10 years	Apr. 17	CF
GSK hails data on Shingles vaccine and gonorrhoea treatment	Apr. 17	AN
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	Apr. 17	MT
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	Apr. 17	MT

	1st Jan change	Capi.
GSK PLC	+13.98%	84.13B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Citi lifts GSK; Shore likes XPS Pensions

Stocks mentioned in the article

Latest news about GSK plc

Chart GSK plc

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for GSK plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals